Quick Answer
OptimizeRx Corp reported Total Revenue of $109.43 million for fiscal year 2025.
OptimizeRx Corp — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $109.43M +18.8% |
$92.13M +28.8% |
$71.52M +14.5% |
$62.45M +1.9% |
$61.29M +41.5% |
$43.31M +76.1% |
| Net Income | $5.13M +125.5% |
-$20.11M -14.5% |
-$17.57M -53.6% |
-$11.44M -3125.4% |
$378.1K +117.1% |
-$2.21M +29.8% |
| Diluted EPS | $0.27 +124.5% |
-$1.10 -6.8% |
-$1.03 -60.9% |
-$0.64 -3300.0% |
$0.02 +113.3% |
-$0.15 +34.8% |
| Total Assets | $176.92M +3.4% |
$171.17M -6.7% |
$183.37M +36.2% |
$134.65M -4.5% |
$140.99M +133.7% |
$60.33M +6.5% |
| Cash and Equivalents | $23.36M +74.6% |
$13.38M -3.4% |
$13.85M -23.9% |
$18.21M -78.5% |
$84.68M +705.2% |
$10.52M -44.2% |
| Long-Term Debt | $21.42M -30.5% |
$30.82M -10.0% |
$34.23M | — | — | — |
| Stockholders Equity | $128.29M +9.7% |
$117.00M -7.6% |
$126.55M +0.4% |
$126.11M -4.0% |
$131.38M +162.9% |
$49.97M +11.4% |
| Operating Income | $11.69M +185.3% |
-$13.71M +48.1% |
-$26.40M -114.8% |
-$12.29M -3503.7% |
$361.1K +116.9% |
-$2.14M +42.2% |
| Gross Profit | $73.59M +23.9% |
$59.38M +38.4% |
$42.90M +10.1% |
$38.97M +9.3% |
$35.64M +47.8% |
$24.11M +56.1% |
| Shares Outstanding | 18.76M +1.7% |
18.45M | — | 18.29M +2.4% |
17.86M +17.3% |
15.22M +4.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $26.07M | +22.3% | -10.7% |
| Net Income | September 30, 2025 | $779.0K | +108.5% | -49.2% |
| Diluted EPS | September 30, 2025 | $0.04 | +108.0% | -50.0% |
| Total Assets | September 30, 2025 | $170.32M | +3.1% | +0.6% |
| Cash and Equivalents | September 30, 2025 | $19.52M | +21.0% | +17.7% |
| Long-Term Debt | September 30, 2025 | $24.80M | -25.5% | -1.3% |
| Stockholders Equity | September 30, 2025 | $122.26M | +6.8% | +2.5% |
| Operating Income | September 30, 2025 | $2.05M | +123.9% | -35.7% |
| Gross Profit | September 30, 2025 | $17.52M | +30.3% | -6.0% |
| Shares Outstanding | September 30, 2025 | 18.59M | — | +0.2% |
- OptimizeRx Corp reported Total Revenue of $109.43 million for fiscal year 2025.
- OptimizeRx Corp showed an increase of +18.8% in Total Revenue compared to the prior fiscal year.
- OptimizeRx Corp reported Net Income of $5.13 million for fiscal year 2025.
- OptimizeRx Corp showed an increase of +125.5% in Net Income compared to the prior fiscal year.
- OptimizeRx Corp reported Diluted EPS of $0.27 per share for fiscal year 2025.
- OptimizeRx Corp showed an increase of +124.5% in Diluted EPS compared to the prior fiscal year.
- OptimizeRx Corp reported Total Assets of $176.92 million for fiscal year 2025.
- OptimizeRx Corp showed an increase of +3.4% in Total Assets compared to the prior fiscal year.
- OptimizeRx Corp reported Cash and Equivalents of $23.36 million for fiscal year 2025.
- OptimizeRx Corp showed an increase of +74.6% in Cash and Equivalents compared to the prior fiscal year.
- OptimizeRx Corp reported Long-Term Debt of $21.42 million for fiscal year 2025.
- OptimizeRx Corp showed a decrease of -30.5% in Long-Term Debt compared to the prior fiscal year.
- OptimizeRx Corp reported Stockholders Equity of $128.29 million for fiscal year 2025.
- OptimizeRx Corp showed an increase of +9.7% in Stockholders Equity compared to the prior fiscal year.
- OptimizeRx Corp reported Operating Income of $11.69 million for fiscal year 2025.
- OptimizeRx Corp showed an increase of +185.3% in Operating Income compared to the prior fiscal year.
- OptimizeRx Corp reported Gross Profit of $73.59 million for fiscal year 2025.
- OptimizeRx Corp showed an increase of +23.9% in Gross Profit compared to the prior fiscal year.
- OptimizeRx Corp reported Shares Outstanding of 18.76 million shares for fiscal year 2025.
- OptimizeRx Corp showed an increase of +1.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: